compare two columns in excel 2013 for differences

The 2-drug regimen dolutegravir (DTG) + lamivudine (3TC) demonstrated non-inferior efficacy, a high barrier to resistance, and a comparable safety profile relative to the 3-drug regimen DTG + tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) at 144 weeks after treatment initiation in the GEMINI-1 and GEMINI-2 trials in ART-naive PWH. Considering the requirement for lifelong ART, the high prevalence of comorbidities among people with HIV (PWH), and the toxicities associated with ART, 2-drug regimens that maintain efficacy comparable to that of 3-drug regimens are of considerable interest and potential value, offering the possibility of reduced cumulative drug exposure, adverse effects, and potential drug interactions. HIV treatment guidelines published by the US Department of Health and Human Services (DHHS) in 2021, the International Antiviral Society–USA (IAS) in 2020, and the European AIDS Clinical Society (EACS) in 2020 recommend integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) with either 1 or 2 nucleoside reverse transcriptase inhibitors for most previously untreated adults and adolescents. These long-term comparative data support the therapeutic value of DTG + 3TC for PWH. These results suggest that the 2-drug regimen DTG + 3TC offers comparable and durable efficacy with fewer serious adverse events vs BIC/FTC/TAF and DTG/ABC/3TC through 144 weeks of treatment in ART-naive PWH. Discontinuations and overall adverse events were similar across all 3 regimens.

Rates of virologic suppression (HIV-1 RNA < 50 copies/mL, US Food and Drug Administration Snapshot analysis) and virologic failure (HIV-1 RNA ≥ 50 copies/mL) as well as mean change in CD4 + cell count were similar with DTG + 3TC, BIC/FTC/TAF, and DTG/ABC/3TC at Week 144. Safety, efficacy, and tolerability results were compared using fixed-effects Bucher ITC methodology to calculate relative outcomes. MethodsĪ systematic literature review identified 4 trials evaluating the treatment regimens of interest in ART-naive PWH (GEMINI-1, GEMINI-2, GS-US-380-1489, and GS-US-380-1490).

This indirect treatment comparison (ITC) was conducted to compare the durability of efficacy and long-term safety of DTG + 3TC vs second-generation, integrase strand transfer inhibitor (INSTI)-based, 3-drug, single-tablet regimens bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and DTG/abacavir/3TC (DTG/ABC/3TC) at Week 144 after treatment initiation. The long-term efficacy and safety of the 2-drug regimen dolutegravir (DTG) + lamivudine (3TC) and 3-drug single-tablet regimens recommended for antiretroviral therapy (ART)-naive people with HIV-1 (PWH) have yet to be compared directly in clinical trials.

Compare two columns in excel 2013 for differences